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Abstract Many companies are now prioritizing the development of dry powder inhalers (DPIs) above pressurized
formulations of asthma drugs. Awell-designed DPI and an appropriate powder formulation can optimize the effective-
ness of inhaled drug therapy.ADPImust be able to delivermedications effectively formostpatients, and anidealinhaler
would provide a dose that does not vary with inspiratory flow rate. Recent regulatory guidelines, among which the
U.S.FDA draft guidance is the most stringent, demand consistent dose delivery from an inhaler throughout its life and
consistency of doses from one inhaler to another.However, the properties of free micronized powders often interfere
with drug handling and with drug delivery, reducing dose consistency. Recent advances in formulation technology can
increaselungdose andreduceitsvariability.While aperfectDPImayneverexist, bothdevice and formulation technology
are evolving to rectifyperceived deficiencies in earlier systems.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1276, available online at http://www.idealibrary.comon
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E¡ective inhalation therapy, using pressurized metered
dose inhalers (pMDIs) and dry powder inhalers (DPIs), is
the cornerstone of asthma management. Inhaled corti-
costeroids are recommended for maintenance therapy
in all patients with persistent asthma, while short-acting
inhaled b2-agonists are the primary rescue medications
in intermittent as well as persistent asthma (1). E¡ective
inhaled corticosteroid therapy will reduce airway in-
£ammation andhyperresponsiveness, improve lung func-
tion, and decrease symptoms. Since the1960s, the pMDI
has been the predominant device for delivering inhaled
asthma drugs. Because of environmental concerns and
inherent design limitations in pMDIs, there has been in-
terest in developing alternative ways to deliver inhaled
drugs. One of the alternatives to the pMDI is the
breath-actuatedDPI, which does notrequire anypropel-
lants.This review examines the design and performance
characteristics of some of the available DPIs. The DPI
and its formulations are evolving so that the DPI couldCorrespondence shouldbe addressed to: S.P.Newman,Pharmaceutical
Pro¢les Limited,MereWay, Ruddington Fields, Ruddington,
NottinghamNG116JS,U.K.Fax: +44 0115 974 8000become the system of choice in many therapeutic situa-
tions.
INHALERDESIGNANDTHEGOALS
OFASTHMAMANAGEMENT
E¡ectiveness and compliance
Although inhaled bronchodilators and corticosteroids
are e¡ective in the treatment of asthma, the incorrect
use of an inhaler by patients can lead to poor compliance
and treatment failure (2). A properly designed inhaler
containing an appropriate formulation can increase ad-
herence and achieve the desired therapeutic e¡ects (3)
andmay also allow a reduction in dosing frequency (4).
A healthcareprovider’s ability to demonstrate the op-
eration of the inhaler and a patient’s capacity to use it are
functions of the design of the inhaler and its inherent
ease of use. The degree of comfort and satisfaction the
patient experiences with the inhaler is a signi¢cant de-
terminant of compliance. It is important that the inhaler
be unobtrusive, durable, easy to hold and operate, and
cost e¡ective (5).Most portable asthma inhalers contain
294 RESPIRATORYMEDICINEmultiple doses, and some type of dose counter is desir-
able for self-management to prevent the use of an empty
inhaler and to allow thepatient to order re¢lls in a timely
manner, as well as allowing the health care provider to
monitor a patient’s compliancewith therapy.
Stable and predictable therapeutic responses require
a consistent dose delivery from an inhaler throughout
its life and consistency of doses from one inhaler to an-
other. Recognizing this, speci¢cations for inhaler dose
uniformity have been de¢ned by regulatory bodies, in-
cluding the European Pharmacopoeia (EP) (6) and the
U.S.Food and Drug Administration (FDA) (7).
Safety
It is also important that any delivery system minimizes
systemic drug exposure, especially to corticosteroids,
particularly because of concern over the potential for
corticosteroids to contribute to systemic side e¡ects, in-
cluding osteoporosis in the elderly, suppression of
growth in children, and suppression of adrenal activity
at any age (8).Tominimize systemic exposure, a corticos-
teroid should be delivered to its target, usually assumed
to be the conducting airways, in the lowestpossible dose
to achieve the desired e¡ects. It has been suggested that
inhalers shouldminimize delivery of particleso1.1mm in
size, which could contribute to systemic exposure after
deposition into the capillary-rich alveolar airspaces (9). It
is also desirable for the corticosteroid to have low oral
bioavailability since part of the administered dose will
be swallowed. Ideally, inhalers shouldminimize orophar-
yngeal deposition since local side e¡ects associated with
inhalation of corticosteroids can include oral candidiasis
and dysphonia (10).
LIMITATIONSOFPMDIS
Propellant
The pMD1 is currently the most common inhaler for
asthma drug delivery and until recently has contained a
suspension or solution of drug in one or more pressur-
ized chloro£uorocarbon (CFC) propellants (11). Strato-
spheric ozone depletion has been attributed in part to
degradation products of CFCs, and more than 140 na-
tions signed the Montreal Protocol in 1987 to control
and phase out any chemical compounds responsible for
ozone loss.This agreement created the opportunity and
motivation to develop new inhaler technology that
would signi¢cantly improve the delivery of aerosol drugs
to the respiratory tract. Alternative propellants for
pMDIs [hydro£uoroalkanes (HFAs)] are being intro-
duced, but these substances also have the potential to
cause environmental problems (12).Other formulation issues in pMDIs
In addition to using CFCpropellants, other drawbacks of
pMDIs arerelated to aerosol formulation andgeneration.
Pressurized MDIs may contain surfactants, such as oleic
acid, that could pose a risk of inducing bronchospasm in
patients su¡ering from advanced airway hyperreactivity
(13). Also, the large size (14) andhigh velocity (15) ofmany
droplets leaving the pMDI nozzle produce extensive or-
opharyngeal deposition (up to 90% of the dose), although
this can be reduced by using a spacer or add-on device
(16).
Ease of use
Patient misuse of pMDIs continues to be problematic.
Correctuse of a pMD1is di⁄cult and leads to a large pro-
portion of patient errors (17). Even healthcare profes-
sionals demonstrate poor knowledge of the use of
pMDIs (18), and therefore it is not surprising that pa-
tients also have trouble using these inhalers correctly.
Breath-actuatedpMDIs (e.g., AutohalerTM [3M] and Easi-
breatheTM [IVAX]) can help to minimize patient coordi-
nation problems (19).
ASPECTSOFDPIDESIGN
Formulation of powders for inhalation
Drugs delivered by DPIs are formulated as either pure
drugormixedwith an inactive excipient.Thebudesonide
preparation for use in theTurbuhalers DPI (AstraZene-
ca) is an example of a pure drug powder formulation.
Powder blends contain micronized particles of the drug
with an excipient, usually lactose, which may be micro-
nized, but which more often comprises larger ‘‘carrier’’
particles.
While the optimal therapeutic particle size distribu-
tion for an inhaleddrypowder asthmamedication is gen-
erally considered to beo5mm, or possibly 1 ^ 5mm (9),
particles this small are typically not free £owing. Cohe-
sion and static charge interferewith drughandlingduring
manufacture and with inhaler ¢lling, can reduce unifor-
mity inmetering individual doses, and can cause drug re-
tention within the device.The use of excipients can help
to improve dose uniformity, partly because a largermass
of powder is generally easier to meter accurately.Under
speci¢c manufacturing conditions, the micronized parti-
cles can be combined to form stabilized agglomerates
with controlled uniformity and hardness. For example, a
novelDPI (Twisthalers, Schering-Plough) uses agglomer-
ates of the corticosteroid mometasone furoate and lac-
tose, stabilized to the appropriate hardness and size for
handling andmetering (20).
Agglomerates of drug particles, or of drug and
lactose, must be deagglomerated by shear forces during
FIG. 1. Examples of inspiratory £ow rates produced by adults
with mild-to-moderate persistent asthma and severe asthma.
Datawere takenwith amodeloftheTwisthalers, and arerepre-
sentative of the preliminary ¢ndings of Kenyon et al. (35).
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the air£ow into the lungs. Particleso5mmin size can be
distributeddeep into the smaller airways (21) and thispe-
netration correlates with good clinical response (22,23).
DPIdesign issues
The design of aDPImustbe coordinatedwith the formu-
lation of the drug. Inhaler design, particularly the geome-
try of themouthpiece, is critical for patients to produce
an air£ow su⁄cient to lift the drug from the dose cham-
ber or capsule, break up the agglomerates in a turbulent
airstream, and deliver a dose to the lungs as therapeuti-
cally e¡ective ¢ne particles (24). The air£ow generated
by inhalation directly determines particle velocity and
hence the easewithwhichparticles are deagglomerated.
The materials used in the construction of DPIs (25)
and characteristics of the formulation (26^28) a¡ect
electrostatic charge accumulation. Some formulations,
as well as inhaler materials, accumulate and retain elec-
trostatic chargemore strongly than others, and this will
a¡ect both drug retention within these inhalers as well
as delivered aerosol behavior.
Air£owrate, inhaler resistance, and aerosol
delivery
The intrinsic resistance to air£ow through aDPI is a ¢xed
property that determines the air£ow rate through the
inhaler in response to the inspiratory e¡ort of the pa-
tient.Each inhaler has a unique resistance and current in-
halers have a wide range of resistance values (29). The
peak inspiratory £ow rate (PIFR, measured in l/min) in-
£uences the e⁄ciency of the inhaler in lifting particles
of the drug formulation from the drug chamber or cap-
sule, and it will also a¡ect the e⁄ciency of deagglomera-
tion of theparticles and the amountof drugreaching into
the lungs (30,31). Ironically, a major advantage of DPIs
(breath-actuation) is closely linked to a signi¢cant disad-
vantage, namely that patients have to inhale through
most DPIs with full inspiratory e¡ort in order to opti-
mize drugdelivery (32). Areduction in inspiratory e¡ort,
andhence in PIFR through the device, is likely to result in
a lower delivery of ‘‘respirable’’ particles from the device
and a reduction in the quantity of drug deposited in the
lungs (32). A patient’s inhalation e¡ort will generate a
higher PIFR through an inhaler with a low air£ow resis-
tance than through an inhaler with a high air£ow resis-
tance. In high-resistance DPIs, interpatient variability in
PIFR may be reduced compared to that through low-re-
sistance devices, leading to more reproducible drug de-
livery (33). However, ¢ne particle production is a
function of speci¢c inhaler design, not simply air£owrate
through the inhaler, and neither inhaler air£ow resis-tance nor PIFR alone can predict how e⁄ciently a DPI
will deliver a drug to the lungs.
An ideal inhaler would provide a dose to the airways
that did not vary with inspiratory £ow rate.The perfor-
mance of DPIs will dependnot only upon the PIFR gener-
ated through the device, but also upon the rate of
increase in £ow, or ‘‘rise time’’ to peak air£ow rate (34).
Measurements of inspiratory £ow pro¢les of patients
with persistent asthma made using a DPI with moder-
ately high air£ow resistance (35) suggest that patients
with a range of asthma severity can use these inhalers.
The inspiratory £owpro¢les of adultswithmild-to-mod-
erate and severe asthma (Fig. 1) allowed comparison of
inspiratory £ow rate, rise time (de¢ned by the time be-
tween10 and 30 l/min), and duration of inhalation. Adults
with severe asthma produced mean PIFRs (457 l/min)
and rise times (o300ms) that were similar to those of
adults with mild-to-moderate asthma, although patients
with mild-to-moderate asthma generally showed longer
durations of inhalation. Thus, even patients with rela-
tively severe asthma appeared to be able to generate
the rise times and PIFRs needed to operate the DPI and
receive an optimal dose.Thosepatientswhowere tested
approximately 3 months later showed similar rise times
andpeak £owrates to those recorded immediately after
training (36). Therefore, with proper training, patients
appeared to remember and perform appropriate inhala-
tion techniques over long periods of time.
EXAMPLESOFDPIDESIGN
Anumber of DPIs have been used to deliver inhaled drug
formulations, and many more are in development. In
296 RESPIRATORYMEDICINETable1,‘‘passive’’or breath-actuatedDPIs are listed.There
are also several ‘‘active’’devices, where the powder is dis-
persedby somemechanism other than thepatient’s inha-
lation, for instance, an internal supply of compressed air
(37, 38).DPIs listed inTable1are divided into several cate-
gories. In ‘‘single-dose’’ devices, individual doses are pro-
vided, usually in gelatin capsules, and have to be loaded
into the inhaler before use. ‘‘Multiple unit dose’’ inhalers
contain a number of individually packaged doses, either
as multiple gelatin capsules or in blisters. In ‘‘multidose’’
devices, drug is stored in a bulk powder reservoir, from
which individual doses aremetered.Table 2 lists some ex-
amples of formulations and dose ranges from a variety of
DPIs.Multidose devices incorporating powder reservoirs
aregenerally capable of deliveringmore than100metered
doses, providing a level of convenience equivalent to a
pMD1. Multiple unit dose devices may o¡er other advan-
tages in terms of more accurate metering of individual
doses and better protection against ingress of moisture,
but are generallymore expensive to produce.
Single-dose devices
While single-dose devices are reusable, they are inconve-
nientbecause an individual dosehas to be loadedinto the
device each time it is used.The Spinhalers (Aventis) was
developed to deliver sodium cromoglycate in individual
gelatin capsules.Thepatient inserts a capsule onto a pro-
peller seated inside the inhalation channel, and the cap-
sule is pierced by two needles that are actuated by a
sliding cam arrangement. When the patient inhales
strongly through the mouthpiece, the propeller turnsTABLE 1. Current and future ‘‘passive’’ (breath-actuated) dry p
Ashurst et al. (38))
Single dose M
Marketed Spinhalers (Aventis)a D
Rotahalers (GSK)
AeroliserTM (Novartis)c Aero
Inhalators (Boehringer)
Eclipse (Aventis)
In development Turbospin (PHand T) Flo
AIRTMInhaler MicroD
(Alkermes) D
T
a Formerly Fisons.
bKnown as Accuhaler in UK.
cAlso known as Cyclohaler (Pharmachemie) and Monohaler (Mia
dAlso known as Inhalator-M.
GSK:GlaxoSmithKline; IB: Innovata Biomed.and vibrates, dispensing the drug as an aerosol (39).The
Rotahalers (GlaxoSmithKline) has been used to deliver
salbutamol and beclomethasone dipropionate.With this
inhaler, a capsule is loaded and a twistmotion causes the
two halves of the capsule to separate and release the
powder. When the patient inhales, the drug is drawn
through a grid and exits the inhaler (40).
Other DPIs intended for purposes other than deliver-
ing asthma drugsmay look very di¡erent.The InhanceTM
DPI (InhaleTherapeutic Systems) is a totally unique sin-
gle-dose device for delivering inhaled peptides and pro-
teins, which are intended to be absorbed via the lungs
into the systemic circulation.The patient loads an indivi-
dual blister into the device, and the powder is dispersed
by compressed air into a chamber mounted on top. By
enabling the patient to inhale a ¢ne particle aerosol
slowly and deeply, conditions for delivering drug into the
alveolated regions of the lungs are optimized (41).
Multiple unit dose devices
The Aerohalers (Boehringer Ingelheim) was the ¢rst
DPI to holdmore than one capsule; a six-capsule inhaler
is currently available.This inhaler has been used to deli-
ver fenoterol and ipratropiumbromide.Themagazine of
capsules is loaded into position, allowing two needles to
pierce a capsule. The patient’s inspiration pulls air
through the holes, vibrating the capsule and delivering
the formulation into the airstream.
The Diskhalers (GlaxoSmithKline) was the ¢rst inha-
ler to use drug formulations prepackaged into single-
dose blisters in a multidose package (42).This inhaler hasowder inhalers (table modi¢ed from Parry-Billings (37) and
ultiple unitdose Multidose
iskhalers (GSK) Turbuhalers (AstraZeneca)
Diskuss (GSK)b Easyhalers (Orion)
halers (Boehringer)d Novolizers (ASTAMedica)
Clickhalers (IB)
Pulvinals (Chiesi)
wcapss (Hovione) Ultrahalers (Aventis)
ose DPI (MicroDose) Taifuns (Focus Inhalation)
elsys DPI (Delsys) MAGhaler (Mundipharma)
echnohalers (IB) Cyclovent (Pharmachemie)
Twisthalers (Schering-Plough)
Airmax (Yamanouchi)
Dispohaler (ACPharma)
Jago DPI (Skyepharma)
t).
TABLE 2. Types of DPIs, formulations, and delivery systems
Example formulations
DPI Drug Formulation Total doseweight Dosing system Doses
Spinhalers
(Aventis)
20mg sodium
cromoglycate
1:1sodium
cromoglycate:lactose
40mg Capsule 1
Rotahalers
(GSK)
200 mg
salbutamol
1:125
salbutamol:lactose
25mg Capsule 1
Inhalators
(Boehringer-Ingelheim)
200 mg fenoterol 1:24
fenoterol:glucose
5.0mg Capsule 1/6
Diskhalers
(GSK)
100 mg
£uticasone
propionate (FP)
1:250 FP:lactose 25mg Blister 4
Diskuss/Accuhalers
(GSK)
50 mg salmeterol 1:250
salmeterol:lactose
12.5mg Blister 60
Turbuhalers
(AstraZeneca)
200 mgbudesonide Budesonide alone 200 mg Reservoir 200
Easyhalers
(Orion)
100 mg
salbutamol
sulfate
1:9.9 salbutamol
sulfate:lactose
10mg Reservoir 200
Twisthalers
(Schering-Plough)
200 mg
mometasone
furoate (MF)
1:5.8 MF:lactose 1.36mg Reservoir 60
Novolizers
(ASTAMedica)
200 mg
budesonide
1:56.5
budesonide:lactose
11.5mg Reservoir 200
GSK denotes GlaxoSmithKline.
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tamol, salmeterol xinafoate, beclomethasone dipropio-
nate, and £uticasone propionate. The inhaler uses re¢ll
disks, each of which contains four or eightblisters.When
the lid of theDiskhaler is opened and closed, the disk ro-
tates and a new blister is available to be pierced.When
the patient inhales through the mouthpiece, the drug
formulation is drawn from the blister and is dispersed as
an aerosol into the respiratory tract.
The Diskuss or Accuhalers (GlaxoSmithKline) has
been used to deliver salbutamol, salmeterol xinafoate,
£uticasone propionate, and a combination of £uticasone
propionate and salmeterol xinafoate (Advairs/Sere-
tides).This inhaler uses a tape of 60 premetered blisters
rather than a disk (43). Movement of a lever opens the
tape, loads the drug into the inhalation channel, and de-
crements the dose counter. The patient’s inspiration
draws the formulation from the inhaler into the lungs.
Multidose devices
TheTurbuhalerswas the ¢rstDPI to dispense dosesme-
tered from a reservoir inside the inhaler (44).The device
has been used to deliver formulations of terbutaline sul-
phate, formoterol, salbutamol or budesonide, or a com-bination of budesonide and formoterol (Symbicorts).
When the patient activates the inhaler by twisting the
base prior to inhalation, theTurbuhalers reservoir sys-
tem deposits a single dose of the drug into a series of
holes in a dosing disk.The turbulence generated in spir-
al-formed channels in the mouthpiece during inhalation
breaks up the agglomerates into ¢ne particles, which
are then inhaled into the lungs. Approximate dose count-
ing is provided by the gradual appearance of a red band
when 20 doses remain. Most Turbuhalers formulations
comprise soft aggregates of micronized drugs formed
into pellets approximately 0.5mm in diameter, without
any excipients.The addition of a spring-operated spacer
device has been suggested to make theTurbuhalers ea-
sier for very young children to use (45).
The Easyhalers (Orion) has been used to deliver sal-
butamol and BDP (46). The reservoir of this inhaler can
hold up to 200 doses. Pushing down the overcap of the
inhaler rotates the metering cylinder at the bottom of
the reservoir, metering a dose of drug and lactose which
is inhaled through the mouthpiece.The Clickhalers (In-
novata Biomed) has a broadly similar design, and has
shown relative £ow rate independence of both lung de-
position (47) and bronchodilator response to salbutamol
(48) over a range of inhaled£owrates.TheTwisthalers is
relatively simple to use because removal of the cap over
298 RESPIRATORYMEDICINEthe mouthpiece automatically meters a dose from the
powder reservoir into a single-dose hole in the dose
plate.
MostDPIs are disposable, but theNovolizers, amulti-
dose reservoir system fromASTAMedica, uses re¢ll car-
tridges of up to 200 single doses of a drug/lactose blend
(49). Formulations in DPIs range from low bulk density,
freely £owing, powders which may be hard to meter ac-
curately, to a compacted block where reproducible dos-
ing should be easier to achieve, but where the powder
maybeharder to disperse (50). An intermediate solution
is o¡ered in the Airmaxs DPI (Yamanouchi Europe)
where air from a collapsing bellows is used to partially
compress powder into the dosing chamber (51).
MORESOPHISTICATED
FORMULATIONS
Traditionally, most DPI formulations have comprised a
blend of micronized drug particles and lactose carrier,
or occasionally aggregates of pure drug particles. For
these formulations,manufacturers have generally sought
to optimize the performance of the system by optimiz-
ing the device, for instance ensuring that the design of
themouthpiece leads to air£ow turbulence andhence ef-
fective deaggregation and a high ¢ne particle dose. In
reality, however, both the device and the formulation af-
fect drug delivery, and there is increasing recognition of
the bene¢ts that can accrue from optimizing the formu-
lation as well as, or perhaps instead of, the device.
Data from the University of London in the early1990s
showed that particle size distributions from DPIs could
be manipulated by changes in the ‘‘rugosity’’ (surface
roughness) of carrier particles (52).This concept was ta-
ken further by Staniforth et al. (53), who developed the
process of ‘‘corrasion’’ to minimize the e¡ect of high-en-
ergybinding sites on lactoseparticles, fromwhichmicro-TABLE 3. Noveldrypowder formulations
Formulation Comp
PowderhaleTM (Passcal)
Fine particle excipients
Large porousparticles A
PulmoSpheresTM In
SoliDoseTM Ela
SEDSTMa In
Nanoparticles Elan
a Solution-enhanced dispersion of supercritical £uids.
b Bradford Particle Design.nized drug particles could be di⁄cult to remove
(PowderhaleTM formulations, Vectura). Improvements in
particle dispersion have also been obtained using ¢ne
particle lactose (54), or ¢neparticle lactose coupledwith
an additional excipient such as spray-dried leucine to
modify the bulk density of the formulation (55).
The formulation in theTwisthalersDPIuses a new ap-
proach to formulation with agglomerates of anhydrous
mometasone furoate, a corticosteroid, and anhydrous
lactose in a low weight ratio (1:5.8) (56). The agglomer-
ates are manufactured as stabilized microcrystalline ar-
rays of drug and excipient that allow ease in handling
and accurate dosemetering.Uniform delivery of mome-
tasone furoate has been shown over a broad range of in-
spiratory £ow rates and times (57,58).
In1997 and1998, Edwards et al. described large porous
particles (59, 60), that have a bulk density of only about
0.1g/cm3.Owing to their lowdensity, theseparticles have
aerodynamic diameters only a fraction of their physical
diameters so that they can penetrate deep into the
lungs. As the number of contact surfaces between adja-
centparticles is reducedwhen theparticles are large, the
particles are readily dispersed in an inhaled airstream
and can provide a relatively inhalation-e¡ort- or £ow-
rate-independent performance. Similar considerations
seem to apply to another porous particle system (Pul-
moSphere particles, Inhale). These and other formula-
tions are listed inTable 3. Sophisticated formulations of
this type have often proved e¡ective in very simple DPIs
(61,62) and thismarks a de¢nite trendwherein the formu-
lation and not the device is being used to control drug
delivery.Hence in a sense the wheel has come full circle,
with greater attentionnowbeing given to optimizing the
formulation than to optimizing the device for somephar-
maceutical products, in some cases allowing companies
to formulate their products in inexpensive single-dose
DPIs.The inconvenience of loading a gelatin capsule into
the device before use need not prove to be a limitingany (if applicable) Reference
Vectura (53)
F (54)
(55)
lkermes (AIR) (59)
(60)
hale (Alliance) (61)
(62)
n (Quadrant) (63)
hale (BPD)b (64)
(NanoSystems) (65)
FIG. 2. Emitteddose as a percentage ofclaimeddeliveryofthe
Spinhalers,Turbuhalers, andDiskhalersacross arangeofinha-
lation £owrates.Data adapted fromde Boer et al. (67).
TABLE 4. Accuracy andreproducibilityof dose emissions from some DPIs invitro (data fromHindle and Byron (66))
Device Drug Mean (% label claim) RSD (%)
Rotahalers Beclomethasone dipropionate 59.5 18.8
Rotahalers Salbutamol 62.7 16.1
Diskhalers Beclomethasone dipropionate 55.4 18.3
Diskhalers Salbutamol 52.0 23.3
Turbuhalers Terbutaline sulphate 62.5 13.7
Turbuhalers Budesonide 58.1 18.3
Spinhalers Sodiumcromoglycate 100.2 7.6
Thetable shows themeanemitteddose expressed as a percentage ofthe statedlabelclaim, and therelative standarddeviation
(RSD) ofthe emitted dose between devices.Datawere obtained at a standardized £owrate of 60 l/min.
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more frequently than once or twice daily. However,
many of these sophisticated formulations may well ¢nd
their main roles outside the ¢eld of asthma therapy, for
instance, to deliver inhaledpeptides and proteins.
INVITROMEASURESOFDPIDRUG
DELIVERY
Dry powder inhalers have tomeet speci¢c standards for
the average drug content of the emitted dose and dose
uniformity. For instance, U.S. FDA draft guidance re-
quires that 90% of inhalers tested must deliver active
drug within 80^120% of the label claim, and that all inha-
lers tested must deliver 75^125% of label claim (7). A
standard method is used to quantify the emitted dose
from a DPI and its variability by collecting the discharge
on a ¢lter.Bymeasuring the emitted dose from the inha-
ler and the retained dose on the inhaler itself, the me-
tered dose and its variability can also be calculated.The
emitted doses from several DPIs are shown in Table 4
from data collectedby Hindle and Byron (66), suggesting
¢rst that some DPIs do not emit a dose consistent with
the stated label claim, and second that the variability in
emitted dosemay be considerable.
Dose uniformity across a range of inspiratory £ow
rates ensures that the patient receives the desired dose
of medication despite variations in inspiratory £ow rate.
The emitted doses of the Spinhalers, Turbuhalers,and
Diskhalers at di¡erent inhalation £ow rates showed sig-
ni¢cant sensitivity of dose delivery to £ow rate in all
three inhalers (Fig. 2) (67).The Diskhalers was themost
sensitive to low £ow rates, emitting o30% of the
claimed label dose at 20 l/min.The fraction of dose deliv-
ered as particles ¢ner than about 5mm in diameter is
usually called the‘‘¢neparticle fraction’’and is sometimes
considered to be predictive of the amount of drug deliv-
ered to the lungs. Since most DPIs are breath actuated,
¢neparticle fractionwill decreasewith a reduction in air-£ow rate through the device. Particle size distributions
produced by DPIs can be measured with a cascade im-
pactor (68,69), which separates airborne particles into
size categories by trapping the particles on a series of
discrete stages.The threemost widely used cascade im-
pactors are the Andersen sampler, multistage liquid im-
pinger, andMarple-Miller impactor, although these three
devices do not necessarily give identical results (70).Each
cascade impactor is calibrated to operate at a speci¢c
air£ow rate butmay bemodi¢ed to operate at di¡erent
£ow rates (71). In order to compare results between in-
halers with di¡ering resistances, current guidelines re-
commend testing DPIs at a ¢xed pressure drop of 4kPa
rather than at a ¢xed £ow rate (68). Since none of the
current instruments is considered ideal, an international
consortium is currently developing an impactor opti-
mized for use in the pharmaceutical environment (72).
300 RESPIRATORYMEDICINEThe use of simulated inhalation pro¢les (73) or inlets to
impactors thatmimic the shape of the human upper air-
ways (74) may provide in vitro data that more closely
match the in vivo situation.
INVIVOMEASURESOFDPIDRUG
DELIVERYANDDISTRIBUTIONIN
THELUNGS
Quanti¢cation of drug deposition in vivo from DPIs may
be carried out using radionuclide imaging methods
(75,76), or by certain pharmacokinetic techniques (77^
79). Radionuclide imaging involves the addition of an ap-
propriate gamma-ray-emitting radionuclide to the for-
mulation, or occasionally into the structure of the drug
molecule itself, and may be in two dimensions (gamma
scintigraphy) or in three dimensions [single photon emis-
sion computed tomography (SPECT) or position emis-
sion tomography (PET)].Whole lung deposition may be
quanti¢ed for some drugs from drug excreted in a 48h
urine collection using the charcoal block pharmacoki-
netic method (77), and indices of lung depositionmay be
provided by the amount of drug appearing in the blood
(78) or in the urine (79) within a few minutes of inhala-
tion. Unlike radionuclide imaging, pharmacokineticTABLE 5. Meanwhole lungdeposition of drugs fromvarious D
Device Drug I
Rotahalers Sodiumcromoglycate Slo
Spinhalers Sodiumcromoglycate Fas
Slo
Diskhalers Salbutamol N
Turbuhalers Budesonide Fas
Slow
Pulvinals Salbutamol Fas
Slo
Easyhalers Salbutamol Fas
Ultrahalers Nedocromil sodium Fas
Slo
Clickhalers Budesonide 35
Taifuns Budesonide Fas
Slo
Cyclohalers AsthmaNCEa Fas
Spiross Budesonide Slo
Fas
Novolizers Budesonide Fas
Slow
Data are for gamma scintigraphic studies in healthy volunteers.
cantlybetweenhealthysubjects andasthmaticswhocaninhale a
blockpharmacokineticmethod are similar to those obtainedby
a Newchemical entity.
b Medianvalues.methods do notprovide anydata on thepattern of distri-
butionwithin di¡erent lung regions.
Whole lung deposition data for a range of DPI pro-
ducts are listed inTable 5, andhave ranged in various stu-
dies from about 5% of the metered dose to about 40%.
Lung deposition is critically a¡ected by the design of the
device, the formulation, and the PIFR attained by the pa-
tient. In comparative studies, DPIs have often deposited
more drug in the lungs than a CFC-based pMDI (89) and
have been clinically e¡ective in correspondingly lower
doses (90). As expected, fast inhalation £ow, involving
maximal inspiratory e¡ort, has usually deposited more
drug in the lungs than slow inhalation £ow, involving sub-
maximal inspiratory e¡ort. However, a number of de-
vices, including some breath-actuated systems, appear
to have deposition characteristics that are virtually inha-
lation-e¡ort independent (47,85), which could make the
devices concerned especially suitable for treating the
very young, the elderly, and those with severe respira-
tory impairment. Scintigraphic images from one DPI
with relatively e¡ort-independent performance are
shown in Fig. 3. The Spiross DPI is unique amongst the
devices listed inTable 5, as the powder is dispersed by an
impeller blade, triggered by an electric motor, rather
thanby the patient’s inhalation.Consequently, this device
depositeddrugmore e⁄ciently in the lungswith slow in-
halation than with fast inhalation (87). Some companiesPIs, expressed as percentofmetered orcapsule dose.
nhalation Deposition (%) Reference
w (60 l/min) 6.2 (30)
t (120 l/min) 13.1 (80)
w (60 l/min) 5.5
otknown 12.4 (81)
t (58 l/min) 27.7 (82)
(36 l/min) 14.8
t (46 l/min) 14.1 (83)
w (28 l/min) 11.7
t (60 l/min) 28.9 (46)
t (75 l/min) 13.3 (84)
w (42 l/min) 9.8
^ 65 l/min 30.8 (47)
t (36 l/min) 34.3 (85)
w (21l/min) 29.6
t (98 l/min) 19.1 (86)
w (15 l/min) 40.5 (87)
t (60 l/min) 30.4
t (99 l/min) 32.1b (88)
(54 L/min) 19.9b
There is no evidence that whole lung deposition di¡ers signi¢-
tthe samePIFRs.Lungdepositiondataobtainedby thecharcoal
gamma scintigraphy.
FIG. 3. Scintigraphic images showing the lung deposition fromone DPI (Taifun) at fast and slowpeak inhaled £owrates.This device
wasrelatively £ow-rate independent inperformance (lungdepositions 34 and 29% ofthe dose, respectively).Data from Pitcairn et al.
(85).Reproduced fromNewmann (76) with permission.
DRYPOWDERINHALERDESIGN,FORMULATION,ANDPERFORMANCE 301have used lung deposition studies to show comparability
between their novel DPI and a well-established ‘‘gold
standard’’device, hence providing a rational basis for the
selection of doses in subsequent pivotal clinical trials
comparing the two devices (88).
In deviceswith a low air£ow resistance, fast inhalation
(maximal inspiratory e¡ort) resulted in a PIFR through
the device of 120 l/min, compared with values of onlyTABLE 6. Some characteristics of anideal DPI, modi¢ed from
E¡ective dosing
E⁄cientdevice
Easy to useabout 30 l/min for devices with very high air£ow resis-
tance. However, in terms of lung deposition, there is no
evidence thatdeviceswith a highresistance to air£oware
any more e⁄cient or any less e⁄cient than low-resis-
tance devices. Each devicemust be treated on itsmerits,
and attempts to predict the performance of one DPI
based on the performance of another one with quite a
di¡erent design have proved unreliable.Ashurst et al. (38)
Uniformdose throughoutthe life of DPI
Targeted, accurate, andreproducible delivery
Generates full dose at lowinspiratory £owrates
Design optimizedbydevice and formulation innovation
Compact, portable
Coste¡ective
Goodmoisture protection
Simple operation
Easy forclinicianto teach and for patientto learn
Dose counter
Mechanismto preventmultiple dosing
Possible to sense dose on backofthroat
302 RESPIRATORYMEDICINECONCLUSION^APPROACHINGTHE
IDEALDPI
There is now clear evidence that many major players in
inhaled drug delivery are prioritizing development of
DPI products in preference to reformulation of pMDIs
with HFA propellants. However, companies developing
DPIs face many challenges, and must often make com-
promises. For instance, seeking solutions to technical
problems associated with optimizing pharmaceutical
performance may introduce incompatibilities with pa-
tient compliance issues. Multidose (reservoir) devices
tend to target drug to the lungs more e⁄ciently than
multiple unit dose devices but tend to have poorer dose
uniformity.While it is unlikely that an ideal DPI will ever
appear, it is at least possible to list some of the charac-
teristics of an ideal DPI (Table 6).
A range of DPIs is alreadymarketed, andmany others
are in development.Not all new DPI devices and formu-
lations will reach the market, but many of those that do
are likely to have successfully addressedperceived limita-
tions in earlier systems. As we go forward into the 21st
century,DPI delivery systems are likely to contribute sig-
ni¢cantly to successful drug delivery by the inhaled
route, not only to treat asthma, but also to deliver a
wider range of drugs intended both for local and sys-
temic applications.
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